-
公开(公告)号：US12295997B2
公开(公告)日：2025-05-13
申请号：US17366946
申请日：2021-07-02
Applicant: Janssen Biotech, Inc.
Inventor： Jason Lee DeHart , Vipul Bhargava , Manuel Alejandro Sepulveda
Abstract: Disclosed herein are self-replicating RNA molecules encoding prostate neoantigens, vaccines, and methods of treating and preventing prostate cancer.
-
公开(公告)号：US20250145711A1
公开(公告)日：2025-05-08
申请号：US18830184
申请日：2024-09-10
Applicant: Janssen Biotech, Inc.
Inventor： Adam Zwolak , Raymond Brittingham , Scott R. Brodeur , Rajkumar Ganesan , Sherry Lynn La Porte , Jinquan Luo , Fang Yi , Colleen M. Kane , Triveni K. Bhatt
Abstract: The disclosure provides antigen binding domains that bind cluster of differentiation 3 (CD3) protein, comprising the antigen binding domains that bind CD3ε, polynucleotides encoding them, vectors, host cells, methods of making and using them.
-
公开(公告)号：US20250145646A1
公开(公告)日：2025-05-08
申请号：US18707865
申请日：2022-11-08
Applicant: JANSSEN BIOTECH, INC.
Inventor： Shalom GOLDBERG , Kristen WILEY , Rhys SALTER
Abstract: The present invention is directed to compounds (macrocyclic compounds) and pharmaceutically acceptable salts thereof, immunoconjugates, radioimmunoconjugates thereof, pharmaceutical compositions containing said compounds and immunoconjugates, radioimmunoconjugates thereof, and the use of said compounds and immunoconjugates, radioimmunoconjugates thereof, in nuclear medicine as tracers and imaging agents.
-
公开(公告)号：US20250109211A1
公开(公告)日：2025-04-03
申请号：US18798473
申请日：2024-08-08
Applicant: JANSSEN BIOTECH, INC.
Inventor： Jenna Goldberg , Jagoda Jasielec , Raluca Verona , Brendan Weiss
IPC: C07K16/28 , A61K31/454 , A61K31/573 , A61K39/00 , A61K39/395 , A61P35/00 , C07K16/30
Abstract: Disclosed are methods of treating cancers and enhancing efficacy of BCMAxCD3 bispecific antibodies. In particular, methods are disclosed of using a BCMAxCD3 bispecific antibody, an anti-CD38 antibody and/or pomalidomide to treat cancers, particularly relapsed or refractory multiple myeloma.
-
公开(公告)号：US12258328B2
公开(公告)日：2025-03-25
申请号：US17822445
申请日：2022-08-26
Applicant: YUHAN CORPORATION , JANSSEN BIOTECH, INC.
Inventor： Hyunjoo Lee , Su Bin Choi , Misong Kim , Young Ae Yoon , Kwan Hoon Hyun , Jae Young Sim , Marian C. Bryan , Scott Kuduk , James Campbell Robertson
IPC: C07D401/14 , C07D413/14 , A61K31/506 , A61P35/00 , A61P37/00 , C07D405/14
Abstract: Provided are 6-membered heteroaryl-containing aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.
-
Patent Agency Ranking
公开(公告)号：US20250019429A1
公开(公告)日：2025-01-16
申请号：US18892683
申请日：2024-09-23
Applicant: Janssen Biotech, Inc.
Inventor： Kristopher Barnthouse , Subinay Ganguly , Maarten Groeneveld , Manuel Lopez, JR. , Michael Nedved , Kevin D. Smith
IPC: C07K16/24
Abstract: Presented here are methods for producing a recombinant anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:38 and a light chain (LC) comprising SEQ ID NO:37 and compositions comprising the recombinant anti-TNF antibody.
-
公开(公告)号：US20250011454A1
公开(公告)日：2025-01-09
申请号：US18703264
申请日：2022-10-19
Applicant: Janssen Biotech, Inc.
Inventor： Adam ZWOLAK , Jason HO , James TESTA, Jr. , Michael Riis HANSEN , Xiefan LIN-SCHMIDT , Ian WHITE , Sanjaya SINGH
Abstract: Provided herein, in certain aspects, is a binding molecule comprising an antigen binding domain and an Fc region; wherein the antigen binding domain is monovalent and the Fc region comprises K248E and T437R mutations (RE mutations), wherein amino acid residue numbering is according to the EU numbering system; wherein the binding molecule has increased capability of hexamerization on a cell surface, and/or increased capability of engaging C1q.
-
公开(公告)号：US20240417693A1
公开(公告)日：2024-12-19
申请号：US18415550
申请日：2024-01-17
Applicant: Janssen Biotech, Inc.
Inventor： Sebastian Rieck , Alireza Rezania
IPC: C12N5/071 , A61K35/39 , C07K14/72 , C12Q1/6806
Abstract: The invention provides for methods of differentiating pancreatic endocrine cells into pancreatic beta cells expressing PDX1, NKX6.1, MAFA, UCN3 and SLC2A. These pancreatic beta cells may be obtained by step-wise differentiation of pluripotent stem cells. The pancreatic beta cells exhibit glucose-dependent mitochondrial respiration and glucose-stimulated insulin secretion similar to islet cells.
-
公开(公告)号：US20240409634A1
公开(公告)日：2024-12-12
申请号：US18691254
申请日：2022-09-12
Applicant: Janssen Biotech, Inc.
Inventor： Patrick John DOONAN , Sherry Lynn LA PORTE , Sanjaya SINGH , Paul Willem Henri lda PARREN , Sabrina Julia Louisa MERAT , Robertus Cornelis ROOVERS , Sara Mohamed A ELASHKAR , Ulrike PHILIPPAR
Abstract: The invention relates to multispecific antibodies and pharmaceutical compositions comprising said antibodies, to processes for the preparation of said antibodies and to the use of said antibodies targeting CD33 and to their use in the treatment of diseases, e.g., cancer.
-
公开(公告)号：US20240409598A1
公开(公告)日：2024-12-12
申请号：US18579062
申请日：2022-07-14
Applicant: Janssen Biotech, Inc. , Protagonist Therapeutics, Inc.
Inventor： Stephanie A. Barros , Charles Hendrick , Santhosh Neelamkavil , Raymond J. Patch , Sandeep Somani , Chengzao Sun , Jing Zhang , Elisabetta Bianchi , Danila Branca , Roberto Costante , Raffaele Ingenito , Ashok Bhandari , Brian Frederick , James Daniel , Tran Trung Tran
Abstract: The present invention relates to novel cyclic peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders. The inhibitor of an interleukin-23 receptor is cyclized by a disulfide bond between penicillamine, cysteine, homocysteine, or alpha methylcysteine residues at positions X4 and X9.
-
-
-
-
-
-
-
-
-
Search Results
1019
records
(took 0.035 seconds)
